Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

Season 9 Episode 42  ·  Nov 16, 2023, 07:45 PM

Headliner
Share
Subscribe

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Share
Subscribe
Next
FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air